21 patients die due to cancer (mortality: 63.6%). At 12 months, progression-free survival was 33.3% in pembrolizumab and 64% in nivolumab. Conclusion: Immunotherapy brought higher survival rate to NSCLC, with good tolerability in most cases, maintaining and improving the quality of life. However, given the disparities between responses, acknowledgment of new targets and biomarkers will make the patient selection for immunotherapy more accurate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.